Biomarker discovery in asthma and COPD by proteomic approaches

Proteomics - Clinical Applications

Volumn 8, Issue 11-12, 2014, Pages 901-915

  Rossi, Rossana ^a   De Palma, Antonella ^a   Benazzi, Louise ^a   Riccio, Anna Maria ^b   Canonica, Giorgio Walter ^b   Mauri, Pierluigi ^a  

^a CNR   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; Biomarkers; COPD; Inflammation; Proteomic approaches

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CARBON MONOXIDE; CATALASE; CERULOPLASMIN; COFILIN 1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C7; FIBRINOGEN; GELATINASE B; GLUTATHIONE PEROXIDASE 1; GLYCOGEN PHOSPHORYLASE; HAPTOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; NITRIC OXIDE; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 5; PHOSPHOLIPASE A2; RETINOL BINDING PROTEIN; SECRETORY COMPONENT; SURFACTANT PROTEIN D; TRANSKETOLASE; VON WILLEBRAND FACTOR; BIOLOGICAL MARKERS; PROTEOME;

ASTHMA; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE MARKER; DOWN REGULATION; EOSINOPHIL; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATIVE STRESS; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SPIROMETRY; SPUTUM ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UPREGULATION; HUMANS; METABOLISM; METHODS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

ASTHMA; BIOLOGICAL MARKERS; HUMANS; PROTEOME; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84912533138     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300108     Document Type: Review

References (90)

1. Global Strategy for Asthma Management and Prevention. December 2012 update. Available at http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html, accessed January 7, 2013.
2. Vestbo, J., Hurd, S. S., Agusti, A. G., Jones, P. W. et al., Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am. J. Respir. Crit. Care Med. 2012, 187, 347-365.
3. Bousquet, J., Jeffery, P. K., Busse, W. W., Johnson, M. et al., From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000, 161, 1720-1745.
4. Hamid, Q., Song, Y. L., Kotsimbos, T. C., Minshall, E. et al., Inflammation of small airways in asthma. J. Allergy Clin. Immunol. 1997, 100, 44-51.
5. Jeffery, P. K., Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998, 53, 129-136.
6. Barnes, P. J., Chronic obstructive pulmonary disease. N. Engl. J. Med. 2000, 343, 269-280.
7. Jeffery, P. K., Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2001, 164, S28-S38.
8. Hasselgren, M, Arne, M., Lindahl, A., Janson, S. et al., Estimated prevalence of respiratory symptoms, asthma and chronic obstructive pulmonary disease related to detection rate in primary health care. Scand. J. Prim. Health Care 2001, 19, 54-57.
9. Mannino, D. M., Buist, A. S., Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370, 765-773.
10. Battaglia, S., den, H. H., Timmers, M. C., Lazeroms, S. P. et al., Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005, 60, 639-464.
11. Montuschi, P., Barnes, P. J., Roberts, L. J., Isoprostanes: markers and mediators of oxidative stress. FASEB J. 2004, 18, 1791-800.
12. Global Initiative for Chronic Obstructive Lung Disease. 2002. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease NHLBI/WHO Workshop Report [online]. NIH Publication, No. 2701. Available at http://www.goldcopd.com, accessed December 12, 2007.
13. Punturieri, A., Szabo, E., Croxton, T. L., Shapiro, S. D. et al., Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J. Natl. Cancer Inst. 2009, 101, 554-559.
14. Mauad, T, Dolhnikoff, M., Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2008, 14, 31-38.
15. Boulet, L. P., Turcotte, H., Hudon, C., Carrier, G. et al., Clinical, physiological and radiological features of asthma with incomplete reversibility of airflow obstruction compared with those of COPD. Can. Respir. J. 1998, 5, 270-277.
16. Fabbri, L. M., Romagnoli, M., Corbetta, L., Casoni, G. et al., Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003, 167, 418-424.
17. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Available at www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm, accessed January 5, 2012.
18. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2010. Available at http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf, accessed June 20, 2011.
19. Boulet, L. P., Asymptomatic airway hyperresponsiveness: a curiosity or an opportunity to prevent asthma?. Am. J. Respir. Crit. Care Med. 2003, 167, 371-378.
20. Ramsdale, E. H., Morris, M. M., Roberts, R. S., Hargreave, F. E., Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 1984, 39, 912-918.
21. Ho, L. P., Wood, F. T., Robson, A., Innes, J. A. et al., Atopy influences exhaled nitric oxide levels in adult asthmatics. Chest 2000, 118, 1327-1331.
22. Silvestri, M., Spallarossa, D., Frangova Yourukova, V., Fregonese, B. et al., Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma. Eur. Respir. J. 1999, 13, 321-326.
23. Fahy, J. V., Kim, K. W., Liu, J., Boushey, H. A., Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 1995, 95, 843-852.
24. Pizzichini, M. M., Popov, T. A., Efthimiadis, A., Hussack, P. et al., Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996, 154, 866-869.
25. Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G. et al., On behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for clinical applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am. J. Respir. Crit. Care Med. 2011, 184, 602-615.
26. Kharitonov, S., Alving, K., Barnes, P. J., Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur. Respir. J. 1997, 10, 1683-1693.
27. Kostikas, K., Koutsokera, A., Papiris, S., Gourgoulianis, K. I. et al., Exhaled breath condensate in patients with asthma: implications for application in clinical practice. Clin. Exp. Allergy 2008, 38, 557-565.
28. Saydain, G., Beck, K. C., Decker, P. A., Cowl, C. T. et al., Clinical significance of elevated diffusing capacity. Chest 2004, 125, 446-452.
29. Global Initiative for Chronic Obstructive Lung Disease. 2013. At-a-glance outpatient management reference for chronic obstructive pulmonary disease (COPD) based on the global strategy for diagnosis management and prevention of COPD. Updated February 2013. Available at http://www.goldcopd.com.
30. Pierce, R., Spirometry: an essential clinical measurement. Aust. Fam. Physician 2005, 34, 535-539.
31. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989, accessed April 14, 2008.
32. Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F. et al., ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 2005, 26, 319-338.
33. Birnbaum, S., Barreiro, T. J., Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement. Chest 2007, 131, 1932-1935.
34. Leung, J. M., Bir, D., Biomarkers in airway diseases. Can. Respir. J. 2013, 20, 180-182.
35. Choi, J., Hoffman, L. A., Rodway, G. W., Sethi, J. M., Markers of lung disease in exhaled breath: nitric oxide. Biol. Res. Nurs. 2006, 7, 241-255.
36. Corradi, M., Pesci, A., Casana, R., Alinovi, R. et al., Nitrate in exhaled breath condensate of patients with different airway diseases. Nitric Oxide 2003, 8, 26-30.
37. Alving, K., Weitzberg, E., Lundberg, J. M., Increased amount of nitric oxide in exhaled air of asthmatics. Eur. Respir. J. 1993, 6, 1368-1370.
38. Kharitonov, S. A., Chung, K. F., Evans, D., O'Connor, B. J. et al., Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care Med. 1996, 153, 1773-1780.
39. Kelly, M. M., Leigh, R., Jayaram, L., Goldsmith, C. H. et al., Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J. Allergy Clin. Immunol. 2006, 117, 989-994.
40. Leigh, R., Pizzichini, M. M., Morris, M. M., Maltais, F. et al., Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006, 27, 964-971.
41. Pizzichini, E., Pizzichini, M., Efthimiadis, A., Hargreave, F. et al., Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur. Respir. J. 1996, 9, 1174-1180.
42. Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B. et al., Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360, 1715-1721.
43. Jayaram, L., Pizzichini, M. M., Cook, R. J., Boulet, L. P. et al., Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur. Respir. J. 2006, 27, 483-494.
44. Siva, R., Green, R. H., Brightling, C. E., Shelley, M. et al., Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007, 29, 906-913.
45. D'Silva, L., Hassan, N., Wang, H. Y., Kjarsgaard, M., et al., Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Can. Respir. J. 2011, 18, 144-148.
46. Gygi, S. P., Rochon, Y., Franza, B. R., Aebersold, R., Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 1999, 19, 1720-1730.
47. Provoost, S., Maes, T., van Durme, Y. M., Gevaert, P. et al., Decreased FOXP3 protein expression in patients with asthma. Allergy 2009, 64, 1539-1546.
48. Iwamoto, H., Gao, J., Koskela, J., Kinnula, V. et al., Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur. Respir. J. 2013, 43, 421-429.
49. Ricciardolo, F. L., Sabatini, F., Sorbello, V., Benedetto, S. et al., Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD. Thorax 2013, 68, 803-811.
50. Csanky, E., Olivova, P., Rajnavolgyi, E., Hempel, W. et al., Monoclonal antibody proteomics: discovery and prevalidation of chronic obstructive pulmonary disease biomarkers in a single step. Electrophoresis 2007, 28, 4401-4406.
51. Röpcke, S., Holz, O., Lauer, G., Müller, M. et al., Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One 2012, 7, e46207.
52. El-Deek, S. E., Makhlouf, H. A., Saleem, T. H., Mandour, M. A. et al., Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Med. Princ. Pract. 2013, 22, 469-474.
53. Gao, P., Zhang, J., He, X., Hao, Y. et al., Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One 2013, 8, e57678.
54. Chen, H., Wang, Y., Bai, C., Wang, X., Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J. Proteomics 2012, 75, 2835-2843.
55. Huerta, A., Crisafulli, E., Menéndez, R., Martínez, R. et al., Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest 2013, 144, 1134-1142.
56. Terracciano, R., Preianò, M., Palladino, G. P., Carpagnano, G. E. et al., Peptidome profiling of induced sputum by mesoporous silica beads and MALDI-TOF MS for non-invasive biomarker discovery of chronic inflammatory lung diseases. Proteomics 2011, 11, 3402-3414.
57. Murphy, V. E., Johnson, R. F., Wang, Y. C., Akinsanya, K. et al., Proteomic study of plasma proteins in pregnant women with asthma. Respirology 2006, 11, 41-48.
58. Gray, R. D., MacGregor, G., Noble, D., Imrie, M. et al., Sputum proteomics in inflammatory and suppurative respiratory diseases. Am. J. Respir. Crit. Care Med. 2008, 178, 444-452.
59. Gomes-Alves, P., Imrie, M., Gray, R. D., Nogueira, P. et al., SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease. Clin. Biochem. 2010, 43, 168-177.
60. Bozinovski, S., Hutchinson, A., Thompson, M., Macgregor, L. et al., Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008, 177, 269-278.
61. Malmström, J., Tufvesson, E, Löfdahl, C. G., Hansson, L. et al., Activation of platelet-derived growth factor pathway in human asthmatic pulmonary-derived mesenchymal cells. Electrophoresis 2003, 24, 276-285.
62. Nishioka, T., Uchida, K., Meno, K., Ishii, T. et al., Alpha-1-antitrypsin and complement component C7 are involved in asthma exacerbation. Proteomics Clin. Appl. 2008, 2, 46-54.
63. Choi, G. S., Kim, J. H., Shin, Y. S., Ye, Y. M. et al., Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin. Exp. Allergy 2013, 43, 730-740.
64. Verrills, N. M., Irwin, J. A., He, X. Y., Wood, L. G. et al., Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183, 1633-1643.
65. Straub, C., Pazdrak, K., Young, T. W., Stafford, S. J. et al., Toward the proteome of the human peripheral blood eosinophil. Proteomics Clin. Appl. 2009, 3, 1151-1173.
66. Rhim, T., Choi, Y. S., Nam, B. Y., Uh, S. T. et al., Plasma protein profiles in early asthmatic responses to inhalation allergen challenge. Allergy 2009, 64, 47-54.
67. Mehrani, H., Ghanei, M., Aslani, J., Golmanesh, L., Bronchoalveolar lavage fluid proteomic patterns of sulfur mustard-exposed patients. Proteomics Clin. Appl. 2009, 3, 1191-1200.
68. Ko, Y. C., Hsu, W. H., Chung, J. G., Dai, M. P. et al., Proteomic analysis of CD4+ T-lymphocytes in patients with asthma between typical therapy (controlled) and no typical therapy (uncontrolled) level. Hum. Exp. Toxicol. 2011, 30, 541-549.
69. Maes, E., Landuyt, B., Mertens, I., Schoofs, L., Interindividual variation in the proteome of human peripheral blood mononuclear cells. PLoS One 2013, 8, e61933.
70. Bandow, J. E., Baker, J. D., Berth, M., Painter, C. et al., Improved image analysis workflow for 2-D gels enables large-scale 2-D gel-based proteomics studies-COPD biomarker discovery study. Proteomics 2008, 8, 3030-3041.
71. Lee, E. J., In, K. H., Kim, J. H., Lee, S. Y. et al., Proteomic analysis in lung tissue of smokers and COPD patients. Chest 2009, 135, 344-352.
72. Pastor, M. D., Nogal, A., Molina-Pinelo, S., Meléndez, R. et al., Identification of proteomic signatures associated with lung cancer and COPD. J. Proteomics 2013, 89, 227-237.
73. Hu, R., Ouyang, Q., Dai, A., Tan, S. et al., Heat shock protein 27 and cyclophilin A associate with the pathogenesis of COPD. Respirology 2011, 16, 983-993.
74. Nicholas, B. L., Skipp, P., Barton, S., Singh, D. et al., Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010, 181, 1049-1060.
75. Ohlmeier, S., Mazur, W., Linja-Aho, A., Louhelainen, N. et al., Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J. Proteome Res. 2012, 11, 599-608.
76. Lo Tam Loi, A. T., Hoonhorst, S. J., Franciosi, L., Bischoff, R. et al., Acute and chronic inflammatory responses induced by smoking in individuals susceptible and non-susceptible to development of COPD: from specific disease phenotyping towards novel therapy. Protocol of a cross-sectional study. BMJ Open 2013, 3, pii: e002178.
77. Reisdorph, N. A., Reisdorph, R., Bowler, R., Broccardo, C., Proteomics methods and applications for the practicing clinician. Ann. Allergy Asthma Immunol. 2009, 102, 523-529.
78. Cederfur, C., Malmström, J., Nihlberg, K., Block, M. et al., Glycoproteomic identification of galectin-3 and -8 ligands in bronchoalveolar lavage of mild asthmatics and healthy subjects. Biochim. Biophys. Acta 2012, 1820, 1429-1436.
79. Izbicka, E., Streeper, R. T., Michalek, J. E., Louden, C. L. et al., Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 2012, 9, 27-35.
80. Gharib, S. A., Nguyen, E. V., Lai, Y., Plampin, J. D. et al., Induced sputum proteome in healthy subjects and asthmatic patients. J. Allergy Clin. Immunol. 2011, 128, 1176-1184.
81. Rosengren, A. T., Nyman, T. A., Lahesmaa, R., Proteome profiling of interleukin-12 treated human T helper cells. Proteomics 2005, 5, 3137-3141.
82. Simões, T., Charro, N., Blonder, J., Faria, D. et al., Molecular profiling of the human nasal epithelium: a proteomics approach. J. Proteomics 2011, 75, 56-69.
83. Bloemen, K., Van Den Heuvel, R., Govarts, E., Hooyberghs, J. et al., A new approach to study exhaled proteins as potential biomarkers for asthma. Clin. Exp. Allergy 2011, 41, 346-356.
84. O'Neil, S. E., Sitkauskiene, B., Babusyte, A., Krisiukeniene, A. et al., Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. Respir. Res. 2011, 12, 124.
85. York, T. P., van den Oord, E. J., Langston, T. B., Edmiston, J. S. et al., High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease. Biomarkers 2010, 15, 367-377.
86. Rana, G. S., York, T. P., Edmiston, J. S., Zedler, B. K. et al., Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Anal. Bioanal. Chem. 2010, 397, 1809-1819.
87. Merkel, D., Rist, W., Seither, P., Weith, A. et al., Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005, 5, 2972-2980.
88. Berg, I., Hanson, C., Sayles, H., Romberger, D., Vitamin D, vitamin D binding protein, lung function and structure in COPD. Respir. Med. 2013, 107, 1578-1588.
89. Bortner, J. D., Jr., Richie, J. P., Jr., Das A., Liao, J. et al., Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J. Proteome Res. 2011, 10, 1151-1159.
90. Franciosi, L., Govorukhina, N., Fusetti, F., Poolman, B. et al., Proteomic analysis of human epithelial lining fluid by microfluidics-based nanoLC-MS/MS: a feasibility study. Electrophoresis 2013, 34, 2683-2694.